Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

EMBO Molecular Medicine(2023)10.15252/emmm.202217367Source: DataRank Database

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors is a research paper published in EMBO Molecular Medicine (2023). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Pending

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Kevin D. Nusser,Kristen L. Jones ORCID,Pushkar Shinde ORCID,Clare Keddy ORCID,Catherine Z. Beach ORCID